Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
20
BHVN Quote, Financials, Valuation and Earnings
Last price:
$35.51
Seasonality move
:
21.02%
Day range:
$36.03 - $37.27
52-week range:
$26.80 - $62.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
11.73x
Volume:
1.2M
Avg. volume:
1M
1-year change:
-16.22%
Market cap:
$3.7B
Revenue:
--
EPS (TTM):
-$9.41
Analysts' Opinion
-
Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Biohaven has an estimated upside of 78.08% from its current price of $36.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $36.66.
Fair Value
-
According to the consensus of 10 analysts, Biohaven has 78.08% upside to fair value with a price target of -- per share.
BHVN vs. S&P 500
-
Over the past 5 trading days, Biohaven has overperformed the S&P 500 by 3.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Biohaven does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biohaven has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Biohaven reported revenues of --.
Earnings Growth
-
Biohaven has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Biohaven reported earnings per share of -$1.70.
Enterprise value:
3.3B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$405.4M | -$495.8M | -$848.9M | -$110.5M | -$178.2M | |
| EBITDA | -$403.7M | -$490.4M | -$841.6M | -$109M | -$176.2M | |
| Diluted EPS | -$11.58 | -$7.22 | -$9.41 | -$1.50 | -$1.70 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $80.6M | $310.6M | $440.5M | |
| Total Assets | -- | -- | $135.6M | $382.7M | $510.5M | |
| Current Liabilities | -- | -- | $28.4M | $62.2M | $152.3M | |
| Total Liabilities | -- | -- | $35.4M | $92.7M | $194.5M | |
| Total Equity | -- | -- | $100.2M | $290M | $316M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$292.3M | -$526.6M | -$94.8M | -$141.3M | |
| Cash From Investing | -- | -$130.3M | -$161.2M | $58.5M | -$93.4M | |
| Cash From Financing | -- | $496.9M | $650.2M | -$39.7M | $80.4M | |
| Free Cash Flow | -- | -$295.1M | -$531.1M | -$96.1M | -$141.9M | |
BHVN
Sector
Market Cap
$3.7B
$45.9M
Price % of 52-Week High
58.93%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-16.23%
-32.15%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$36.46
200-day SMA
Sell
Level
$42.62
Bollinger Bands (100)
Sell
Level
38.29 - 50.27
Chaikin Money Flow
Buy
Level
26.8M
20-day SMA
Sell
Level
$40.46
Relative Strength Index (RSI14)
Sell
Level
35.84
ADX Line
Sell
Level
16.97
Williams %R
Buy
Level
-80.7187
50-day SMA
Sell
Level
$46.08
MACD (12, 26)
Sell
Level
-2.92
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
67.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Stock Forecast FAQ
In the current month, BHVN has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHVN average analyst price target in the past 3 months is --.
-
Where Will Biohaven Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biohaven share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Biohaven?
Analysts are divided on their view about Biohaven share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biohaven is a Sell and believe this share price will drop from its current level to --.
-
What Is Biohaven's Price Target?
The price target for Biohaven over the next 1-year time period is forecast to be -- according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHVN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biohaven is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BHVN?
You can purchase shares of Biohaven via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biohaven shares.
-
What Is The Biohaven Share Price Today?
Biohaven was last trading at $35.51 per share. This represents the most recent stock quote for Biohaven. Yesterday, Biohaven closed at $36.66 per share.
-
How To Buy Biohaven Stock Online?
In order to purchase Biohaven stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 1.85% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 10.92% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is down 3% over the past day.
